Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Sabatolimab + Spartalizumab||Case Reports/Case Series||Actionable||In a Phase Ib/II trial, MBG453 and Spartalizumab (PDR001) combination treatment resulted in stable disease in 5 patients with melanoma, including cutaneous melanoma (n=2), uveal melanoma (n=2), and non-cutaneous melanoma (n=1) (AACR Annual Meeting 2019, Abstract CT183; NCT02608268).||detail...|
|PubMed Id||Reference Title||Details|
|Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies||Full reference...|